Ftse Mib
33.388,65
0,22%
DAX
18.104,08
-0,11%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
65.240,33
0,16%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX) Notizie

Neurocrine Biosciences Inc

NBIX
130,86
-4,43 (-3,27%)
19 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/6/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202414:01PRNUSNeurocrine Biosciences Presented CAHtalyst™ Phase 3..
03/6/202413:35PRNUSNeurocrine Biosciences Announces Publication of Primary..
03/6/202413:30PRNUSNeurocrine Biosciences Announces Publication of Primary..
30/5/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:53EDGAR2Form 144 - Report of proposed sale of securities
29/5/202422:01PRNUSNeurocrine Biosciences to Participate at Investor..
28/5/202422:14PRNUSNeurocrine Biosciences Announces CEO Succession Plan
28/5/202414:30PRNUSNeurocrine Biosciences to Present New Phase 3 CAHtalyst™..
24/5/202400:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202422:01EDGAR2Form 8-K - Current report
21/5/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:05PRNUSNeurocrine Biosciences Announces Publication of Phase 3..
17/5/202422:32EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:31EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:31EDGAR2Form 144 - Report of proposed sale of securities
16/5/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202414:30PRNUSNeurocrine Biosciences Presented Baseline Data from the..
09/5/202415:45PRNUSNeurocrine Biosciences Presents CAHtalyst™ Adult Study..
09/5/202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
08/5/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
07/5/202422:15PRNUSNeurocrine Biosciences to Present at the BofA Securities..
07/5/202414:30PRNUSNeurocrine Biosciences to Present Phase 3 Baseline..
06/5/202414:30PRNUSNeurocrine Biosciences Supports Tardive Dyskinesia Awareness..
03/5/202419:15PRNUSNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study..
01/5/202413:00PRNUSNeurocrine Biosciences Reports First Quarter 2024 Financial..
30/4/202423:12PRNUSNeurocrine Biosciences Announces U.S. FDA Approval of..
24/4/202414:30PRNUSNeurocrine Biosciences Launches WHAT THE C@H?! Educational..
23/4/202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
16/4/202422:01GLOBESentia Medical Sciences and Neurocrine Biosciences Extend..
10/4/202422:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
03/4/202414:30PRNUSNeurocrine Biosciences Announces First-Patient Dosed in..
Apertura: 135,82 Min: 130,63 Max: 136,50
Chiusura: 135,29

La tua Cronologia

NASDAQ
NBIX
Neurocrine Biosciences
BIT
F18375
Vontobel Financial Produ...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network